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ABSTRACT
Objective: Acute coronary syndromes (ACS) are
common, but their incidence and outcome might
depend greatly on how data are collected. We
compared case ascertainment rates for ACS and
myocardial infarction (MI) in a single institution using
several different strategies.
Methods: The Hull and East Yorkshire Hospitals serve
a population of ∼560 000. Patients admitted with ACS
to cardiology or general medical wards were identified
prospectively by trained nurses during 2005. Patients
with a death or discharge code of MI were also
identified by the hospital information department and,
independently, from Myocardial Infarction National
Audit Project (MINAP) records. The hospital laboratory
identified all patients with an elevated serum troponin-
T (TnT) by contemporary criteria (>0.03 µg/L in 2005).
Results: The prospective survey identified 1731
admissions (1439 patients) with ACS, including 764
admissions (704 patients) with MIs. The hospital
information department reported only 552 admissions
(544 patients) with MI and only 206 admissions (203
patients) were reported to the MINAP. Using all 3
strategies, 934 admissions (873 patients) for MI were
identified, for which TnT was >1 µg/L in 443, 0.04–
1.0 µg/L in 435, ≤0.03 µg/L in 19 and not recorded in
37. A further 823 patients had TnT >0.03 µg/L, but did
not have ACS ascertained by any survey method.
Of the 873 patients with MI, 146 (16.7%) died during
admission and 218 (25.0%) by 1 year, but ranging
from 9% for patients enrolled in the MINAP to 27%
for those identified by the hospital information
department.
Conclusions: MINAP and hospital statistics grossly
underestimated the incidence of MI managed by our
hospital. The 1-year mortality was highly dependent on
the method of ascertainment.
BACKGROUND
Although acute coronary syndromes (ACS),
including myocardial infarction (MI), are
common, there is a lack of robust epidemio-
logical data about their incidence.1 Case ascer-
tainment and selection bias could have a
major impact on incidence and outcome statis-
tics. This creates difficulty in planning appro-
priate resource allocation, doubt about the
efficacy of coronary prevention at a population
level and uncertainty about the overall effect-
iveness of management of ACS.
In late 1998, the UK launched the
Myocardial Infarction National Audit Project
(MINAP) and required all hospital trusts to
report all MIs initially and subsequently a much
broader range of patients.2 About 1 million
KEY QUESTIONS
What is already known about this subject?
▸ Myocardial infarction (MI) is common, but the
effect of the method of case ascertainment on
its epidemiology has not been adequately
explored.
▸ The prognosis of MI managed by cardiologists
has improved markedly over the last 20 years
but this could, at least in part, reflect the
method of case ascertainment and selection.
▸ Plasma concentrations of troponins are often
elevated in the absence of a clinically identified
cardiac event.
What does this study add?
▸ This study shows that the incidence and
outcome of MI is highly dependent on the mode
of ascertainment.
▸ It demonstrates that a raised troponin that is not
associated with other features of an acute coron-
ary syndrome (ACS) is associated with a particu-
larly poor prognosis.
How might this impact on clinical practice?
▸ The observations will increase awareness of the
uncertainty surrounding the incidence and
outcome of ACS, the need for improved data col-
lection and a review of resource requirements
for the management of ACS.
▸ Further research may help improve diagnosis,
management and outcomes for patients who do
not have ACS, but have a raised troponin.
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cases of MI have been reported to the MINAP over the last
15 years.3 (https://www.ucl.ac.uk/nicor/audits/minap/
reports) These reports suggest that the quality of care for
ACS in the UK is good or excellent. However, there are
deep concerns about the completeness of, and case selec-
tion for, the MINAP returns that might misrepresent the
true pattern of care.
We conducted a retrospective audit of all patients
coded as having MI in our region in 1998. This identi-
fied 896 patients; of whom, 562 (63%) subsequently
developed heart failure and 480 (54%) died during
∼6-year follow-up.4 We now report a new audit of MIs
occurring in 2005 from the same region using the same
and three additional methods for case ascertainment.
This method gave us the opportunity of comparing the
hospital incidence of MI using three different
approaches and additionally making a historical com-
parison from the same region at a time of major
changes in treatment and services.
METHODS
Study population
One hospital group in Hull and East Yorkshire provides
all the acute cardiac services for ∼560 000 people; of
whom, ∼300 000 are aged >35 years, living in a geo-
graphically distinct part of the UK. The Hull Infarction
Project (HIP-2005) employed specialist cardiac nurses to
try to identify all patients with ACS admitted during
2005 to the acute assessment or cardiac monitoring
units and other medical wards. Case records were
reviewed to verify the medical diagnosis, use of loop
diuretics and serum concentrations of troponin T
(TnT); results of imaging tests were obtained whenever
available and treatment at discharge was recorded. The
hospital information department provided all death and
discharge data for acute MI and a record of all patients
reported to the MINAP in 2005. We also received a
report of all positive (>0.03 µg/L) TnT tests. Survival
status was recorded until June 2014.
HIP-2005 definitions
Clinical criteria
ACS was defined as a diagnosis made by a cardiologist or,
if the TnT was elevated, by a cardiac specialist nurse or a
non-specialist doctor. ACS was subclassified as an MI or
unstable angina by cardiologists. When the cardiologist
did not specify, patients who had an elevated TnT or ST
segment elevation on the ECG were considered to have
had an MI and those who did not were reported as
unstable angina. Patients with sudden death or cardiac
arrest that was considered likely to be due to an ACS were
included in the survey and considered to have had an MI
if they had left bundle branch block (LBBB) or ST
segment elevation or had a pre-existing increase in TnT.
Assessments of left ventricular function within 1 year
after discharge were recorded. Criteria for left ventricu-
lar systolic dysfunction (LVSD) were left ventricular
ejection fraction <40% or a qualitative report of moder-
ate or severe LVSD on echocardiography, first-pass radio-
nuclide ventriculography or contrast angiography.
Serum TnT was defined as positive if >0.03 µg/L and
strongly positive if >1.0 µg/L. High-sensitivity TnT was
not introduced until after December 2010.
MINAP criteria
The MINAP seeks to enrol all patients with symptoms
suggestive of an ACS admitted to the hospital in
England and Wales (population ∼50 million),5 although
we suspect, in practice, that many hospitals report only
patients who have been considered for thrombolysis or
coronary intervention. From January 2004 until March
2005, 88 782 patients were reported to have had an MI
by the MINAP.6 The discharge diagnosis of ACS is made
by the medical staff caring for the patient in the light of
standard investigations, including clinical history, ECG
and troponin. Patients’ data were entered by the clinical
audit staff into a central database.5 7
Hospital coding system
The hospital employs specialised coding staff who review
and code the case notes of all deaths and discharges
regardless of cause, including data from postmortem
examinations, using ICD-10.8 The codes are used to gen-
erate central returns to the NHS and for reimburse-
ment. Acute MI was coded as I21, subsequent MI as I22,
silent MI as I25.6 and complications following acute MI
as I23.
Laboratory-positive TnT
Serum TnT (Roche Diagnostics) was measured in a
single laboratory for the whole region. Values >0.03 µg/
L were considered positive. We collected all positive tro-
ponins, and the hospital information department pro-
vided us with the discharge diagnosis of patients who
had a positive TnT, but were not diagnosed as ACS by
any of the other three methods.
Statistical analysis
Data were analysed using SPSS (V.16.0). Categorical data
are presented as percentages and continuously distribu-
ted data as median and IQR. Estimating the probability
of death at day 30, 1 and 3 years was calculated by using
moving average estimator curves in patients who had
TnT report after dividing them into patients with and
without a diagnosis of ACS.
Survival curves are plotted by the Kaplan-Meier
method and compared by the log-rank test. An arbitrary
level of 5% statistical significance (two-tailed) is
assumed.
RESULTS
Overall results
Of 1764 admissions identified with ACS by HIP-2005, 33
were excluded from further analysis because they had
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Figure 1 (A) Incidence of ACS and MI identified by the HIP. (B) Incidence of MI identified by the hospital information
department (HID). (C) Incidence of MI identified by the MINAP. (D) Laboratory report of TnT during 2005 and sequence of
mortality until the end of 2008. ACS, acute coronary syndromes; HIP, Hull Infarction Project; MI, myocardial infarction; MINAP,
Myocardial Infarction National Audit Project; TnT, troponin T.
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been transferred from another region. This left 1439
unique patients with 1731 admissions for the main ana-
lysis; of which, 292 were readmissions within the same
year, including 148 with one readmission and 55 with
multiple readmissions. Of the 1731 admissions identified
in HIP-2005, 764 (704 patients and 60 readmissions)
were classified as MI and 967 (735 patients and 232
readmissions) as angina (figure 1A). During the index
hospitalisation, only about half were managed, at least in
part, by a consultant cardiologist and only 199 (14%)
patients had percutaneous transluminal coronary
angioplasty.
Using the hospital information department, only 552
admissions with MI (544 patients and 8 readmissions)
were identified. Using the MINAP, only 206 admissions
(203 patients and 3 readmissions) for MI were identified
(figure 1B, C).
Of the 764 admissions (704 patients) identified by
HIP-2005 with MI, 388 (381 patients) were also identified
by hospital discharge codes and 186 (183 patients) by the
MINAP. Hospital discharge codes identified an additional
164 admissions (163 patients) with MI not identified by
HIP-2005; of whom, 140 patients had an elevated TnT,
including 80 who had values >1.0 µg/L. In addition, five
patients were identified as having MI by the MINAP but
not by other methods; two of these were identified as
angina by HIP-2005, three had a negative troponin and
two had no record of troponin being measured. Overall,
the three methods of surveillance identified 933 admis-
sions (872 patients) with MI and 1896 admissions (1603
patients) with ACS (figures 2 and 3A, B).
The laboratory reported 7945 TnT tests (2300 with
positive TnT) in 5852 patients during 2005. After
excluding patients from regions other than those in the
hospitals primary catchment area, of the 1679 patients
with a positive TnT, 823 patients were not reported as
having ACS by any of the other three routes of ascertain-
ment. Eighty-five (10%) of these had values of TnT
>1 µg/L. These patients were older than those in the
other groups (figure 1D and table 1).
For patients enrolled through the HIP-2005 survey, ST
segment elevation MI (STEMI) was present in 328
(23%) patients on their first admission, and an add-
itional nine patients had STEMI during readmission.
Seventy-one (5%) patients had LBBB; of whom, 43 were
diagnosed as having angina and 28 were managed as
having MI. Thrombolysis was given to 227 of 356 (64%)
patients during their first admission and an additional
four patients on readmission. The ‘door-to-needle’ time
was available for 228 admissions and the median time
was 30 min (IQR 20–63). This compares to 203 patients
with STEMI or MI with LBBB identified by the Hull
MINAP (of whom, 3 had a further readmission with
STEMI); of whom, 197 received thrombolysis with a
door-to-needle time of 30 (IQR 20–51) min. Similar data
were not available for patients identified by the hospital
information department or laboratory TnT.
Table 2 summarises the ICD-10 discharge codes for
the 823 patients with positive TnT but not reported as
ACS. For the three commonest diagnosis, namely heart
failure, infections and chest pain, the median ages were
77 (70–83), 81 (74–88) and 75 (64–82) years; of which,
Figure 2 Incidence of MI in all
three data sets HIP, HID and
MINAP. HIP, Hull Infarction
Project; MI, myocardial infarction;
MINAP, Myocardial Infarction
National Audit Project.
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56 (41%), 64 (50%) and 42 (41%) were women,
respectively.
Mortality according to TnT during first admission in all
patients identified by HIP-2005, HID, MINAP and
laboratory-positive TnT
Overall, 2426 individual patients were identified by
HIP-2005, HID, MINAP or a positive TnT as potentially
having an ACS. Among these, serum TnTwas ≤0.03 µg/L
in 708, >0.03–1.0 µg/L in 1188, >1.0 µg/L in 474
and was the test not performed in 56 patients (figure 4
and table 3).
Of the 1662 patients with elevated TnT, only 839
(50%) were diagnosed with ACS by one of the survey
methods. Of the 1547 patients with ACS by at least one
survey method, 708 (46%) had a negative TnT. Patients
with values of TnT >0.03 µg/L had a higher mortality
rate, but mortality was similar regardless of
Figure 3 (A) Patients with MI
identified by HIP, HID and MINAP
with highest TnT in 2005. (B)
Patients with ACS identified by
HIP, HID and MINAP with highest
TnT in 2005. ACS, acute
coronary syndromes; HIP, Hull
Infarction Project; MI, myocardial
infarction; MINAP, Myocardial
Infarction National Audit Project;
TnT, troponin T.
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Table 1 Patient characteristics recorded during the index admission (data are median (IQR) and number occurring (%))
Variables ACS-HIP MI-HIP MI-HInfoD MI-MINAP TnT +ve only
Any case
(ACS, MI or TnT +ve)
N 1439 704 544 203 823 2426
Age (years) 67 (58–77) 69 (59–78) 71 (60–80) 65 (56–73) 77 (69–84) 72 (61–81)
Age >75—men 181 (21%) 113 (24%) 95 (27%) 18 (13%) 211 (47%) 440 (32%)
Age >75—women 224 (38%) 117 (49%) 102 (54%) 18 (29%) 250 (67%) 511 (50%)
Women 591 (41%) 241 (34%) 189 (35%) 63 (31%) 375 (46%) 1029 (42%)
TnT ≥0.03* µg/L 724 (50%) [34] 678 (98%) [13] 510 (99%) [27] 191 (96%) [4] 823 1698 (71%) [51]
TnT >1.0* µg/L 324 (23%) [34] 323 (47%) [13] 335 (65%) [27] 163 (82%) [4] 85 (10%) 491 (21%) [51]
History of diabetes 227 (16%) 104 (15%) n n 166 (20%) n
History of MI 246 (17%) 103 (15%) n n n n
History of hypertension 541 (38%) 255 (36%) n n n n
Loop diuretic µg/L 305 (21%) 162 (23%) n 15 (12%) [81] n n
Aspirin 1027 (71%) [2] 517 (74%) [2] n 144 (97%) [55] n n
ACE inhibitor 589 (41%) [1] 374 (53%) [1] n 121 (92%) [71] n n
Angiotension receptor blocker 82 (6%) [1] 30 (4%) [1] n 2 (3%) [127] n n
β blocker 873 (61%) [1] 473 (67%) [1] n 120 (91%) [71] n n
Aldosterone antagonist 59 (4%) [1] 37 (5%) [1] n 5 (4%) [82] n n
Statin 979 (68%) 513 (73%) n 132 (95%) [64] n n
Report on LV function available 703 [736] 409 [295] 293 [251] 125 [78] 298 [525] 1055 [1371]
LVSD 236 (34%) 173 (42%) 142 (48%) 47 (38%) 134 (45%) 401 (38%)
Sodium 139 (137–141) [18] 139 (137–140) [2] 139 (136–140) [3] 138 (136–140) [1] 138 (136–141) [8] 139 (137–141) [27]
K 4.3 (4–4.5) [71] 4.3 (4–4.6) [23] 4.3 (4–4.6) [24] 4.2 (4–4.5) [8] 4.3 (3.9–4.7) [43] 4.3 (4.0–4.6) [122]
eGFR† 69 (53–83) [18] 64 (49–79) [2] 64 (44–77) [3] 69 (54–85) [1] 48 (31–68) [11] 62 (43–78) [33]
eGFR <60‡ 473 (33%) 279 (40%) 230 (43%) [3] 66 (33%) 539 (66%) 1109 (46%)
eGFR <30 94 (6.5%) 67 (9.5%) 66 (12.1%) 9 (4.4%) 191 (23%) 321 (13%)
WCC 8.6 (6.9–10.9) [28] 9.9 (7.8–12.2) [10] 10.7 (8.35–13.6) [13] 10.6 (8.5–13.1) [2] 10.7 (8.1–14.5) [21] 9.3 (7.2–9.3) [55]
Diabetic 252 (17.5%) 119 (16.9%) 83 (15.3%) 24 (11.8%) 166 (20%) 443 (18%)
Anaemia in first available Hb§ 333 (24%) [27] 193 (28%) [10] 165 (31%) [13] 37 (18%) [2] 451 (56%) [21] 861 (36%) [57]
In-patient mortality 87 (6%) 78 (11%) 104 (19%) 10 (5%) 209 (25%) 342 (14%)
30-day Mortality 96 (7%) 84 (12%) 101 (19%) 12 (6%) 187 (23%) 343 (14%)
One-year mortality 179 (12%) 134 (19%) 149 (27%) 19 (9%) 334 (41%) 597 (25%)
Overall mortality by end of 2008 301 (21%) 203 (29%) 202 (37%) 29 (14%) 472 (57%) 877 (36%)
Overall mortality by June 2014 542 (38%) 326 (46%) 283 (52%) 55 (27%) 600 (73%) 1269 (52%)
[Numbers in italics in square brackets are numbers of patients with missing data].
Any case means a patient who belonged to any one of the other groups.
*Double-counting is possible because some patients had multiple admissions with a positive troponin, only some of which were identified as admissions with ACS.
†Four-variable formula derived from the modification of diet in renal disease study (4V MDRD), GFR=186×(Creat/88.4)−1.154×Age−0.203×0.742 if female ×1.212 if African Caribbean, was
used to estimate the GFR.
‡eGFR <60 was defined as eGFR <60 mL/min/1.73 m2.
§Anaemia: WHO criteria for anaemia are used (man <13 g/dL and woman <12 g/dL).
ACS, acute coronary syndrome; any case, all ACS-HIP (MI and unstable angina in HIP), MI-HID, MI-MINAP and TnT +ve; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration
rate; HInfoD, Hospital Information Department; HIP, Hull Infarction Project; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; MINAP, Myocardial Infarction National Audit
Project; TnT +ve, positive troponin T; WCC, white cell count.
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concentration above this (figure 5A). Patients with a
positive TnT who were not identified as having ACS
(figure 5B) by one of the survey methods had a worse
prognosis (41%) at 1 year than those with ACS (figure
5C), whether the patients with ACS were TnT-positive
(mortality 23%; p=0.0001) or not (mortality 6%;
p=0.0001). Patients with ACS also had worse mortality at
30 days and at 3 years (figure 5B). Survival was poorest
in patients with a positive TnT test and no ACS
(p<0.001) compared to the other two groups (figure 6).
Loop diuretic and survival after discharge
Information on diuretic treatment was available in 1439
patients with ACS from the HIP-2005 population. Of the
703 patients with TnT ≤0.03 µg/L, 698 survived the
index admission and 126 (18%) were discharged on
loop diuretic, and 572 were not discharged on a loop
diuretic; of whom, 34 (27%) and 42 (7%), respectively,
had died by the end of 2008. Of the 700 patients with
TnT >0.03 µg/L included in HIP-2005, 633 survived the
index admission and 144 (23%) were and 489 (77%)
were not discharged on a loop diuretic; of whom, 67
(47%) and 69 (14%) had died by the end of 2008
(figure 7).
Table 2 Discharge diagnosis in patients with elevated
TnT who were not diagnosed as ACS by any of the three
methods of ascertainment (N=823)
First
diagnosis
Second
diagnosis
Chest pain 103 13
Heart failure 137 27
Stroke 28 5
Seizure 4 0
Cardiac arrest 10 3
Ventricular tachycardia 16 2
Supraventricular tachycardia 41 41
Pulmonary thromboembolism 15 3
Other cardiovascular 43 4
Ischaemic heart disease 44 18
Renal disease 17 46
Cancer 51 11
Septicaemia 21 7
Infection 129 37
Chronic obstructive pulmonary
disease
61 5
Trauma or fracture 35 0
Haemorrhage 2 2
Other 49 2
Not reported 17 0
ACS, acute coronary syndrome; TnT, troponin T.
Figure 4 Mortality by the end of 2008 from first admission in all patients with ACS identified by HIP, HID, MINAP and positive
TnT in 2005. ACS, acute coronary syndromes; HIP, Hull Infarction Project; MINAP, Myocardial Infarction National Audit Project;
TnT, troponin T.
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Left ventricular function
Of the 1352 patients with ACS identified by HIP-2005
who survived the index admission, no record of an
assessment of LV function could be identified for 685
(51%) patients from their case notes or hospital systems
during the subsequent year. Of the 667 patients who
had LV function assessed, 206 patients (30%) had LVSD.
Mortality by the end of 2008 was 31% in those with
LVSD, 12% in those without LVSD and 14% for those
with no report of LV function.
DISCUSSION
The present report demonstrates that the incidence of
ACS is highly dependent on the method of ascertain-
ment, with a 10-fold difference depending on the
criteria applied. An audit may appear excellent when
applied to a subset of carefully selected patients; but
when applied to all those requiring care, it may appear
poor. We found that no single survey method identified
>60% of the 2426 patients who might have had ACS.
The incidence of MI also varied threefold depending on
the method of ascertainment. Herrett et al9 also indi-
cated that fewer than 50% of MIs reported in electronic
records, such as Hospital Episode Statistics (HES) or
Clinical Practice Research Database (CPRD), were
reported to the MINAP. Our data extend this observa-
tion to other methods that can be used to identify
patients with ACS. The high mortality among patients
with a raised TnT on a ‘first-generation’ assay but who
were not identified by any other survey method is also
cause for concern. Clearly, surveys that focus on
Table 3 Mortality during index admission, 1 year, by end of 2008 and June 2014 according to serum TnT concentration
All
In-patient
mortality
One-year
mortality
Overall mortality
by end of 2008
Overall mortality
by June 2014
TnT ≤0.03 µg/L 708 7 (1%) 42 (6%) 84 (12%) 202 (29%)
TnT 0.03–1 µg/L 1188 220 (19%) 393 (49%) 582 (49%) 787 (66%)
TnT >1 µg/L 474 86 (18%) 133 (28%) 180 (38%) 242 (51%)
TnT not reported 56 29 (52%) 29 (52%) 31 (55%) 38 (68%)
TnT, troponin T.
Figure 5 Probability of death within 30 days, 1 year and 3 years according to the TnT level in 2005. For all three figures, the Y
axis is the probability of death. The X axis is TnT drawn on a log-10 scale. ACS, acute coronary syndromes; TnT, troponin T.
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cardiology wards and coronary interventions are likely to
miss many patients admitted with ACS to services other
than cardiology, especially in high-risk groups such as
older people or those with other important medical
comorbidities.
Our data from 2005 suggest an annual incidence of
MI of 1.56 per thousand population; of ACS of 2.86 per
thousand and of ACS or positive TnT of 4.33 per thou-
sand. In our region, using MI identified by hospital dis-
charge statistics alone, the incidence of MI had dropped
by 40% from 1.66 per thousand per year in 1998 to 0.97
in 2005. This compares to 64 436 admissions in England
for acute MI using hospital episode statistics, which gives
a rate of 1.29 per thousand in 2005.10 Of these, 49 017
patients were reported as having STEMI11 and 13 489
with non-STEMI,12 which suggests substantial under-
reporting of non-STEMI. However, many previous
reports have quoted incidence rates excluding younger
people from the denominator.1 If only those people
aged >35 years are considered, our local incidence of MI
is closer to 3 per thousand. These data are also likely to
be an underestimate of the rate of MI in the community,
as up to 30% of people with an MI may die before they
reach hospital,13 14 and up to 40% of patients who
survive an MI do not have symptoms that trigger urgent
referral to the hospital.15–18
About half of the patients with a positive TnT were not
identified as having ACS by any of the survey methods.
There are reasons other than ACS for elevation in TnT,
including strenuous exercise, heart failure, trauma, renal
failure, sepsis, gastrointestinal bleeding, pulmonary
embolism and myocarditis.19–24 Others have also
reported a higher mortality rate in patients without cor-
onary disease but with elevated serum troponin.25 It is
likely that the clinical diagnosis of ACS was missed in
some cases and uncertain in others. Some of these
patients may have has, so called, type-2 MI reflecting
myocardial energy demand/supply imbalance rather
than an acute vascular occlusion.26–28 For instance, in
patients with heart failure, TnT is often elevated, espe-
cially (although not exclusively) during acute exacerba-
tions.29 Postmortem data suggest that there is a
substantial rate of MI in this population that is not asso-
ciated with classical symptoms.30 31 The high mortality
rate among patients with elevated TnT who were not
identified as having ACS may well indicate heart and/or
renal failure. Newer, high-sensitivity assays for troponin
will increase the diagnostic sensitivity for ACS but at the
potential cost of a substantial decline in specificity and
Figure 6 Survival curves are plotted by the Kaplan-Meier
method, showing 3-year mortality according to the TnT level in
2005 in patients with TnT test (TnT-positive–No ACS (n=823),
TnT-positive–ACS (n=840) and TnT negative–ACS (n=707)).
ACS, acute coronary syndromes; TnT, troponin T.
Figure 7 Use of loop diuretics as a general indicator of adverse outcome. ACS, acute coronary syndromes; HIP, Hull Infarction
Project; TnT, troponin T.
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an increase in diagnostic confusion.32 33 Indeed, these
new assays may have greater clinical utility in the heart
failure outpatient clinic than in the emergency
room.33 34
In contrast to a previous report,35 on far fewer
patients, we found that 3-month mortality was similarly
high in patients with a raised troponin on a ‘first-
generation’ assay whether the elevation was modest or
substantial. Our hospital policy, in 2005, was to measure
TnT once at least 12 hours after the onset of symptoms.
Single measurements may be a poor guide to the extent
of myocardial damage. Alternatively, even modest
increases in TnT may indicate the presence of unstable
plaque and the threat of further events that provoke
arrhythmias or cause substantial cardiac damage.
The outcome from MI in our unselected population
remains very different from that reported among
patients in randomised controlled trials of ACS. The
exclusion of high-risk, elderly patients with multiple
comorbidities from trials probably accounts for most of
the disparity. However, failure to refer patients for cardi-
ology advice and to undertake timely intervention may
also contribute to poor outcomes. Nevertheless,
in-patient mortality for MI in our hospital dropped from
22% in 1998, a mortality that was consistent with that
predicted by the international GRACE score,36 to 11%
in 2005; some of this difference might be accounted for
by differences in survey method. Since this survey, a
regional primary angioplasty service has been implemen-
ted that may have improved outcomes further. As noted
in the present and previous studies,37 it is patients who
develop clinical evidence of heart failure who fare par-
ticularly badly. Heart failure precedes the majority of
deaths after MI.38 Patients with substantial symptoms or
signs of congestion require treatment with loop diuretics
and, therefore, their prescription can be considered a
sensitive marker of the development of heart failure.
However, prescription of loop diuretics may lack specifi-
city for a diagnosis of heart failure; cardiac imaging and
biomarkers should be used to confirm the diagnosis.
CONCLUSION
The incidences of ACS and MI are highly dependent on
the method of case ascertainment. Failure to identify
older, high-risk patients leads to overoptimistic estima-
tions about the prognosis of ACS, underestimation of
the resources needed to manage it and misleading per-
ceptions about the adequacy of care that might lead to
complacency. An increase in TnT and the use of diure-
tics are simple clinical markers of an adverse prognosis.
Even a slight elevation in TnT is associated with a poor
outcome whether or not a patient is diagnosed with
ACS. Mortality was higher among patients with a positive
TnT who did not have a documented diagnosis of ACS,
which may partly reflect the age and underlying disease
in this patient group, but could also reflect suboptimal
management of cardiovascular risk.
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